Literature DB >> 18945595

Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps.

Siegbert Rieg1, Anja Huth, Hubert Kalbacher, Winfried V Kern.   

Abstract

The role of clinically important multidrug resistance (MDR) efflux pumps in bacterial resistance to various human antimicrobial peptides (AMPs), including cathelicidin LL-37, the alpha-defensins human neutrophil peptides (HNPs)-1-3 and HD-5 and the beta-defensins hBD-2 and -3, was investigated. AMP susceptibility testing was performed by killing assays and standard minimal inhibitory concentration assays. AMP susceptibility was determined in Escherichia coli and Pseudomonas aeruginosa strains overexpressing resistance-nodulation-cell division (RND)-type pumps AcrAB and MexAB, respectively, and in their pump-deficient parental strains. Furthermore, the impact of a member of the major facilitator (MF) efflux pump family was investigated in Staphylococcus aureus overexpressing NorA and in wild-type strains. The E. coli AcrAB and P. aeruginosa MexAB RND-type efflux pumps as well as the S. aureus NorA MF efflux pump were unable to confer resistance to AMPs. These findings do not support a critical role of MDR efflux pumps in the tested pathogens as a strategy to increase virulence by circumventing the antimicrobial action of innate defence AMPs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945595     DOI: 10.1016/j.ijantimicag.2008.07.032

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

Review 1.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 2.  Bacterial strategies of resistance to antimicrobial peptides.

Authors:  Hwang-Soo Joo; Chih-Iung Fu; Michael Otto
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-05-26       Impact factor: 6.237

Review 3.  Bacterial resistance mechanisms against host defense peptides.

Authors:  Tomaz Koprivnjak; Andreas Peschel
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

4.  Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa.

Authors:  Marina Berditsch; Thomas Jäger; Nikola Strempel; Thomas Schwartz; Jörg Overhage; Anne S Ulrich
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

5.  Skin bacteria after chlorhexidine exposure-is there a difference in response to human beta-Defensin-3?

Authors:  M Reichel; A Heisig; P Heisig; G Kampf
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-27       Impact factor: 3.267

Review 6.  Mechanisms of resistance to antimicrobial peptides in staphylococci.

Authors:  Hwang-Soo Joo; Michael Otto
Journal:  Biochim Biophys Acta       Date:  2015-02-17

7.  Antibacterial properties of an oligo-acyl-lysyl hexamer targeting Gram-negative species.

Authors:  Fadia Zaknoon; Keren Goldberg; Hadar Sarig; Raquel F Epand; Richard M Epand; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

8.  Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa.

Authors:  Momen Askoura; Walid Mottawea; Turki Abujamel; Ibrahim Taher
Journal:  Libyan J Med       Date:  2011-05-13       Impact factor: 1.657

9.  Host Antimicrobial Peptides in Bacterial Homeostasis and Pathogenesis of Disease.

Authors:  Derek R Heimlich; Alistair Harrison; Kevin M Mason
Journal:  Antibiotics (Basel)       Date:  2014-12-01

Review 10.  Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance.

Authors:  Fernanda Guilhelmelli; Nathália Vilela; Patrícia Albuquerque; Lorena da S Derengowski; Ildinete Silva-Pereira; Cynthia M Kyaw
Journal:  Front Microbiol       Date:  2013-12-09       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.